News Updates
Scope

Wed, May 27, 2026

1 updates
AZN
2:00 AM

US FDA decision date on camizestrant extended

27 May 2026 US FDA decision date extended for SERENA-6 filing of camizestrant to enable review of additional data The US Food and Drug Administration (FDA) has informed AstraZeneca that it will extend the Prescription Drug User Fee Act (PDUFA) date to review additional data requested to support the New Drug Application (NDA) for camizestrant in combination...

Presentation / Abstract • Phase 3ASCO presentation Tue, Jun 2, 2026astrazeneca.com

Tue, May 26, 2026

3 updates
AZN
2:00 AM

Camizestrant recommended for breast cancer in EU

26 May 2026 Camizestrant in combination with a CDK4/6 inhibitor recommended for approval in the EU by CHMP for 1st-line advanced ER-positive breast cancer Recommendation based on SERENA-6 Phase III trial results which showed combination reduced the risk of disease progression or death by 56% in patients with an emergent ESR1 tumour mutation If approved,...

astrazeneca.com
AZN
2:00 AM

Enhertu recommended in EU for HER2+ solid tumours

26 May 2026 Enhertu recommended for approval in the EU by CHMP for patients with previously treated HER2-positive metastatic solid tumours Based on three Phase II trials of AstraZeneca and Daiichi Sankyo's Enhertu which showed clinically meaningful responses across a broad range of tumours If approved, Enhertu would become the first HER2-directed therapy...

astrazeneca.com
AZN
2:00 AM

Datroway approved in US for 1L triple-negative BC

26 May 2026 Datroway approved in the US as first TROP2-directed antibody drug conjugate for 1st-line treatment of patients with metastatic triple-negative breast cancer who are not PD-1/PD-L1 inhibitor candidates AstraZeneca and Daiichi Sankyo's Datroway is the only TROP2-directed antibody drug conjugate to prolong overall survival in this setting vs....

astrazeneca.com

Mon, May 18, 2026

3 updates
AZN
10:00 AM

Director/PDMR Shareholding

18 May 2026 Transaction by Person Discharging Managerial Responsibilities AstraZeneca PLC (the Company) announced that, on 14 May 2026, an award of the Company's ordinary shares of $0.25 each (Ordinary Shares) vested to Pascal Soriot, Executive Director and Chief Executive Officer, under the terms of the AstraZeneca Performance Share Plan (AZPSP)....

astrazeneca.com
AZN
2:05 AM

Enhertu approved in two HER2+ early BC settings

18 May 2026 Enhertu approved in the US for two new indications for patients with HER2-positive early breast cancer Approved for use before surgery based on DESTINY-Breast11 Phase III trial Approved for use following surgery based on DESTINY-Breast05 Phase III trial Two new indications bring AstraZeneca and Daiichi Sankyo's Enhertu into curative-intent...

astrazeneca.com
AZN
2:00 AM

Baxfendy approved in the US for hypertension

18 May 2026 Baxfendyapproved in the US as the first and only aldosterone synthase inhibitortreatment for adults with hypertension Approval based on BaxHTN Phase III results showing statistically significant and clinically meaningful reduction in systolic blood pressure in patients with uncontrolled or resistant hypertension Baxfendy 2mg lowered systolic...

astrazeneca.com

Thu, May 14, 2026

1 updates
AZN
2:00 AM

Imfinzi + EV improves EFS & OS in bladder cancer

14 May 2026 Perioperative Imfinzi plus neoadjuvant EV showed statistically significant and clinically meaningful improvements in event-free survival and overall survival in muscle-invasive bladder cancer in the Phase III VOLGA trial Perioperative Imfinzi plus Imjudo and neoadjuvant EV showed a statistically significant and clinically meaningful improvement...

Interim Data • Phase 3Interim data Thu, May 14, 2026astrazeneca.com

Fri, May 1, 2026

3 updates
AZN
10:00 AM

Total Voting Rights and Admission of Shares

1 May 2026 Total Voting Rights and Notification of Admission of Further Securities to Trading (PRM 1.6.4R) Total Voting Rights The following notification is made in accordance with the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1....

astrazeneca.com
AZN
2:05 AM

FDA ODAC vote on camizestrant in breast cancer

01 May 2026 Update on FDA Advisory Committee vote on camizestrant in combination with a CDK4/6 inhibitor for advanced HR-positive breast cancer The US Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) did not reach a majority vote in favor of the benefit risk profile of AstraZeneca's camizestrant in combination with a...

astrazeneca.com
AZN
2:00 AM

FDA ODAC recommends Truqap in prostate cancer

01 May 2026 Truqap recommended by FDA Advisory Committee for PTEN-deficient metastatic hormone-sensitive prostate cancer ODAC overwhelming majority voted that Truqap plus abiraterone and ADT demonstrated a favourable benefit risk profile for patients based on the CAPItello-281 Phase III trial results First and only targeted treatment combination to...

astrazeneca.com

Wed, Apr 29, 2026

1 updates
AZN
2:00 AM

1st Quarter Results

29 April 2026 AstraZeneca results: Q1 2026 Strong revenue growth and positive readouts from high-value NMEs reinforce confidence in 2030 ambition Revenue and EPS summary [][] Q1 2026 % Change $m Actual CER[1] - Product Sales 14,386 12 7 - Alliance Revenue 825 29 26 Product Revenue 15,211 13 8 Collaboration Revenue 77 4 - Total Revenue 15,288 13 8 Reported...

astrazeneca.com

Tue, Apr 28, 2026

1 updates
AZN
2:27 AM

Breztri approved in the US for asthma

28 April 2026 Breztri approved in the US for asthma as first and only triple therapy for patients 12 years of age and older Approval based on KALOS and LOGOS Phase III trials demonstrating statistically significant and clinically meaningful benefits of AstraZeneca's single-inhaler fixed-dose triple therapy compared with inhaled dual therapy Approval is...

astrazeneca.com

Mon, Apr 27, 2026

1 updates
AZN
2:00 AM

Saphnelo self-administration approved in the US

27 April 2026 Saphnelo approved in the US for subcutaneous self-administration as a new autoinjector for the treatment of systemic lupus erythematosus First-in-class Saphnelo Pen now offers greater flexibility and convenience, reaching a wider group of patients AstraZeneca's Saphnelo (anifrolumab) has been approved in the US for self-administration as a...

astrazeneca.com

Thu, Apr 23, 2026

1 updates
AZN
2:00 AM

Directorate change

23 April 2026 Change to AstraZeneca Board of Directors AstraZeneca congratulates Rene Haas on his appointment as Chief Executive Officer of SoftBank Group International, in addition to his position as Chief Executive Officer of Arm Holdings plc....

astrazeneca.com

Tue, Apr 21, 2026

1 updates
AZN
2:00 AM

I CAN PhIII interim analysis met primary endpoint

21 April 2026 Ultomiris demonstrated statistically significant and clinically meaningful reduction of proteinuria in adults with immunoglobulin A nephropathy in I CAN Phase III trial Ultomiris delivered rapid reduction in proteinuria as early as week 10 Results show potential for terminal C5 complement inhibition with Ultomiris as a disease-modifying...

Trial Results • Phase 3astrazeneca.com

Mon, Apr 20, 2026

1 updates
AZN
2:00 AM

Third tozorakimab positive Phase III in COPD

20 April 2026 Tozorakimab met primary endpoint in Phase III MIRANDA trial in patients with COPD Third positive pivotal Phase III clinical trial of AstraZeneca's IL-33-targeting biologic further demonstrates its benefits in COPD Positive high-level results from the pivotal Phase III MIRANDA trial showed potential first-in-class tozorakimab demonstrated a...

Trial Results • Phase 3astrazeneca.com

Thu, Apr 9, 2026

1 updates
AZN
12:25 PM

Result of AGM

9 April 2026 Results of Annual General Meeting held on 9 April 2026 AstraZeneca PLC announced the results of the voting at its Annual General Meeting (AGM) today. As proposed in the Notice of AGM, all Resolutions were decided by poll vote. Resolutions 10 - 13 were passed as special resolutions; all other resolutions were passed as ordinary resolutions....

astrazeneca.com

Thu, Apr 2, 2026

1 updates
AZN
2:21 AM

Imfinzi+Imjudo improves PFS in early liver cancer

2 April 2026 Imfinzi plus Imjudo combined with lenvatinib and TACE demonstrated a statistically significant and clinically meaningful improvement in progression-free survival in embolisation-eligible unresectable liver cancer in EMERALD-3 Phase III trial Imfinzi plus Imjudo combined with lenvatinib and transarterial chemoembolisation (TACE) showed trend...

Trial Results • Phase 3astrazeneca.com

Wed, Apr 1, 2026

1 updates
AZN
10:00 AM

Total Voting Rights and Admission of Shares

1 April 2026 Total Voting Rights and Notification of Admission of Further Securities to Trading (PRM 1.6.4R) Total Voting Rights The following notification is made in accordance with the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1....

astrazeneca.com

Tue, Mar 31, 2026

1 updates
AZN
2:00 AM

Efzimfotase alfa Ph3 program show positive results

This announcement contains inside information 31 March 2026 Efzimfotase alfa demonstrated positive results from global Phase III clinical programme in hypophosphatasia MULBERRY randomised, placebo-controlled trial showed efzimfotase alfa demonstrated statistically significant and clinically meaningful improvement in bone health in treatment-na•ve paediatric...

Trial Results • Phase 3astrazeneca.com

Fri, Mar 27, 2026

1 updates
AZN
3:14 AM

Tozorakimab met OBERON/TITANIA primary endpoints

This announcement contains inside information 27 March 2026 Tozorakimab met primary endpoint in both OBERON and TITANIA Phase III trials in patients with COPD First-ever IL-33-targeting biologic to demonstrate statistically significant and highly clinically meaningful reductions in COPD exacerbations in two replicate Phase III clinical trials Positive...

Trial Results • Phase 3astrazeneca.com

Fri, Mar 20, 2026

1 updates
AZN
7:00 AM

Notification of Admission of Shares

20 March 2026 Notification of Admission of Further Securities to Trading (PRM 1.6.4R) AstraZeneca PLC (the Company) announced today the following information in accordance with The Public Offers and Admissions to Trading Regulations 2024 (POATRs) PRM 1.6.4R....

astrazeneca.com

Mon, Mar 16, 2026

1 updates
AZN
3:00 AM

Imfinzi approved in EU for early gastric cancer

16 March 2026 Imfinzi approved in the EU as first and only perioperative immunotherapy for patients with early gastric and gastroesophageal cancers Approval based on MATTERHORN Phase III trial demonstrating statistically significant and clinically meaningful improvements in event-free survival and overall survival AstraZeneca's Imfinzi (durvalumab) in...

astrazeneca.com

Tue, Mar 10, 2026

1 updates
AZN
7:00 AM

Notice of AGM

10 March 2026 Notice of Annual General Meeting AstraZeneca PLC (the Company) announced today the publication of its Notice of Annual General Meeting 2026 and Shareholders' Circular (the Notice). The Company's Annual General Meeting (AGM) will be digitally-enabled and will be held on Thursday 9 April 2026 at 14:30 (BST)....

astrazeneca.com

Fri, Mar 6, 2026

3 updates
AZN
6:10 AM

Director/PDMR Shareholding

6 March 2026 Transaction by Person Discharging Managerial Responsibilities AstraZeneca PLC (the Company) announced that, on 5 March 2026, an award of the Company's ordinary shares of $0.25 each (Ordinary Shares) vested to Pascal Soriot, Executive Director and Chief Executive Officer, under the terms of the AstraZeneca Performance Share Plan (AZPSP)....

astrazeneca.com
AZN
6:05 AM

Director/PDMR Shareholding

6 March 2026 Transactions by Persons Discharging Managerial Responsibilities AstraZeneca PLC (the Company) announced that, on 4 March 2026, awards of the Company's ordinary shares of $0.25 each (Ordinary Shares) vested to certain Persons Discharging Managerial Responsibilities of the Company (PDMRs) under the terms of the AstraZeneca Deferred Bonus Plan...

astrazeneca.com
AZN
6:00 AM

Director/PDMR Shareholding

6 March 2026 Transactions by Persons Discharging Managerial Responsibilities AstraZeneca PLC (the Company) announced that, on 4 March 2026, certain Persons Discharging Managerial Responsibilities of the Company (PDMRs) were granted awards of the Company's ordinary shares of $0.25 each (Ordinary Shares) under the terms of the AstraZeneca Deferred Bonus Plan...

astrazeneca.com